US FDA gets tough on financial disclosures by clinical investigators
This article was originally published in RAJ Devices
The US Food and Drug Administration has substantially revised its guidance on the disclosure of financial interests by clinical investigators and is seeking stakeholder feedback on the draft document1,2. The revised guidance addresses concerns that the FDA does not do enough to guard against financial conflicts of interest among physicians, who carry out clinical trials of pharmaceuticals and medical devices that have yet to receive marketing authorisation.
You may also be interested in...
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.